Estrogen replacement therapy: Difference between revisions
Jump to navigation
Jump to search
imported>Gareth Leng No edit summary |
imported>Robert Badgett (started adverse effects) |
||
| Line 7: | Line 7: | ||
The promotion of estrogen replacement therapy in [[scientific journal]]s has been controversial due to the role of [[conflict of interest]]s and ghost writing. | The promotion of estrogen replacement therapy in [[scientific journal]]s has been controversial due to the role of [[conflict of interest]]s and ghost writing. | ||
:“You can't just put another name on the article, but you can plagiarize the way we did when we wrote papers in college. What you need to do is give your potential | :“You can't just put another name on the article, but you can plagiarize the way we did when we wrote papers in college. What you need to do is give your potential authors Karen's version of the article before the author modified it. Then have your authors modify it for publication nder their name. Wyeth owns Karen's draft, not the final publication”.<ref>Fugh-Berman AJ (2010) The Haunting of Medical Journals: How Ghostwriting Sold “HRT”. PLoS Med 7(9): e1000335. {{doi|10.1371/journal.pmed.1000335}}</ref> | ||
==Adverse effects== | |||
Estrogen replacement therapy may cause [[urolithiasis]].<ref name="pmid20937929">{{cite journal| author=Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K et al.| title=Postmenopausal hormone use and the risk of nephrolithiasis: Results from the Women's Health Initiative hormone therapy trials. | journal=Arch Intern Med | year= 2010 | volume= 170 | issue= 18 | pages= 1678-85 | pmid=20937929 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20937929 | doi=10.1001/archinternmed.2010.342 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 07:01, 21 October 2010
In medicine, estrogen replacement therapy is "the use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, dyspareunia, and progressive development of osteoporosis. This may also include the use of progestational agents in combination therapy."[1]
Stopping estrogen replacement therapy is difficult.[2]
The promotion of estrogen replacement therapy in scientific journals has been controversial due to the role of conflict of interests and ghost writing.
- “You can't just put another name on the article, but you can plagiarize the way we did when we wrote papers in college. What you need to do is give your potential authors Karen's version of the article before the author modified it. Then have your authors modify it for publication nder their name. Wyeth owns Karen's draft, not the final publication”.[3]
Adverse effects
Estrogen replacement therapy may cause urolithiasis.[4]
References
- ↑ Anonymous (2024), Estrogen replacement therapy (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Lindh-Astrand L, Bixo M, Hirschberg AL, Sundström-Poromaa I, Hammar M (2010 Jan-Feb). "A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms.". Menopause 17 (1): 72-9. DOI:10.1097/gme.0b013e3181b397c7. PMID 19675505. Research Blogging.
- ↑ Fugh-Berman AJ (2010) The Haunting of Medical Journals: How Ghostwriting Sold “HRT”. PLoS Med 7(9): e1000335. DOI:10.1371/journal.pmed.1000335
- ↑ Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K et al. (2010). "Postmenopausal hormone use and the risk of nephrolithiasis: Results from the Women's Health Initiative hormone therapy trials.". Arch Intern Med 170 (18): 1678-85. DOI:10.1001/archinternmed.2010.342. PMID 20937929. Research Blogging.